Austin, Texas, 30th August 2020
Evolution Biotechnologies Inc., the company extending the use of biological control into medically important areas, today announced the publication of a chapter on phage therapy written by its CEO, Dr. David R. Harper.
Entitled “Selection of Disease Targets for Phage Therapy”, the chapter has been published on line by Springer Nature, prior to its inclusion in the book “Bacteriophages: Biology – Technology – Therapy” (http://www.springer.com/gb/book/9783319419855) to be published in early 2021.
Dr. Harper is the Editor-in-Chief of the book, working with Dr. Ben Burrowes, Dr. Malcolm McConville, and Professor Steve Abedon.
Dr. Harper said “This book will provide a key, wide-ranging resource for the sector as a whole, and we are all looking forward to its publication after years of work”.
About Evolution Biotechnologies
Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections, a key cause of both veterinary and human infections.
About phage therapy
Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.